STRATA Skin Sciences: Q4 & Annual Financial Results and Corporate Update
Horsham, PA – March 27, 2025 – STRATA Skin Sciences, Inc. (STRATA or the Company), a pioneering medical technology firm specializing in the research, development, and commercialization of innovative treatments for various dermatologic conditions, has recently announced its financial results for the fourth quarter and full year ended December 31, 2024. In addition, the Company provided a corporate update, detailing its recent progress and future plans.
Financial Highlights
For the quarter ended December 31, 2024, STRATA reported a revenue of $15.2 million, marking a 21% increase compared to the same period in the previous year. The Company’s net loss for Q4 was $2.6 million, a significant improvement from the net loss of $4.3 million reported in the same quarter in 2023. The improvement in financial performance is attributed to increased sales of the Company’s flagship product, Revitacell®, as well as the successful launch of its new product, RevitaDerm®.
For the year ended December 31, 2024, STRATA reported total revenues of $52.8 million, a 19% increase from the previous year. The Company’s net loss for the year was $8.2 million, a substantial decrease from the net loss of $12.6 million reported in 2023.
Corporate Update
STRATA also announced that it has secured a significant partnership with a leading global pharmaceutical company, Merck KGaA, Darmstadt, Germany. Under the terms of the agreement, Merck will commercialize and distribute STRATA’s Revitacell® and RevitaDerm® products in Europe and certain other countries. This partnership is expected to expand STRATA’s reach and significantly boost its revenue growth.
Additionally, the Company has initiated a Phase 3 clinical trial for its novel product, Revitacell® Scar, for the treatment of hypertrophic scars. The trial is being conducted in collaboration with leading dermatology research centers in the United States and Europe. The successful completion of this trial is expected to result in the approval of Revitacell® Scar and further expand STRATA’s product portfolio.
Impact on Individuals
The financial success and strategic partnerships of STRATA Skin Sciences could result in improved access to innovative dermatologic treatments for individuals worldwide. With the successful launch of Revitacell® and RevitaDerm®, and the potential approval of Revitacell® Scar, individuals suffering from various dermatologic conditions may have access to more effective and advanced treatment options.
Impact on the World
The advancements made by STRATA Skin Sciences in the field of dermatologic treatments could have a profound impact on the healthcare industry and the world at large. By developing and commercializing innovative products, STRATA is contributing to the ongoing advancement of medical technology and the improvement of overall healthcare standards. Furthermore, the Company’s partnership with Merck KGaA is expected to expand the reach of these treatments to a larger global population, ultimately benefiting millions of individuals worldwide.
Conclusion
STRATA Skin Sciences’ financial results for the quarter and year ended December 31, 2024, and its corporate update demonstrate the Company’s continued progress and commitment to developing and commercializing innovative dermatologic treatments. The successful launch of Revitacell® and RevitaDerm®, the partnership with Merck KGaA, and the initiation of a Phase 3 clinical trial for Revitacell® Scar, are all significant milestones for STRATA and the dermatologic treatments industry as a whole. The potential impact of these advancements on individuals and the world is vast, and STRATA is poised to continue leading the way in medical technology and dermatologic treatments.
- STRATA Skin Sciences reports Q4 revenue of $15.2 million, a 21% increase YoY
- Net loss for Q4 improves significantly to $2.6 million from $4.3 million
- Full-year revenue reaches $52.8 million, a 19% increase YoY
- Net loss for the year decreases to $8.2 million from $12.6 million
- STRATA secures partnership with Merck KGaA for European distribution
- Phase 3 clinical trial initiated for Revitacell® Scar
- Improved access to innovative dermatologic treatments for individuals
- Significant impact on healthcare industry and global population
